Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 9/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085618 | 0.89 | PTGER4 (0.58) | PTGER4PTGDRPTGER2PHGDH | |
| SCHEMBL13619519 | 0.85 | PTGER4 (0.48) | PTGER4GPR139ALDH1A1LMNAPTGDR | |
| SCHEMBL12584141 | 0.83 | PTGER4 (0.48) | PTGER4GPR139PTGDRTP53P2RX3 | |
| SCHEMBL12948788 | 0.83 | PTGER4 (0.48) | PTGER4PTGDRACACBPTGER2PHGDH | |
| SCHEMBL12584531 | 0.82 | CYP1A2 (0.47) | PTGER4GPR139PTGDRTP53PHGDH | |
| SCHEMBL12948790 | 0.81 | P2RX3 (0.46) | PTGER4GPR139PTGDRACACBPTGER2 | |
| SCHEMBL10086358 | 0.80 | PTGER4 (0.70) | PTGER4GPR139PTGDRPTGER2 | |
| SCHEMBL12900495 | 0.80 | PTGER4 (0.70) | PTGER4GPR139PTGDRPTGER2 | |
| SCHEMBL12584692 | 0.79 | RAB9A (0.58) | PTGER4ACACBPTGER2PHGDHP2RX3 | |
| SCHEMBL12900450 | 0.79 | F10 (0.54) | TP53PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460787-A1 | Amide compounds and their use as PGE2 antagonists. | Astellas Pharma Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20110028463-A1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028463-A1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2172447-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028463-A1 | AMIDE COMPOUNDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885GPR139 115/4885ALDH1A1 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.